06 October 2021
Visiongain has published a new report entitled the Pharma Wholesale and Distribution Market Report 2021-2031: Forecasts by Type (Full-Line Wholesalers (FLWs), Short-Line Wholesalers (SLWs), Direct-to-Pharmacy (DTP), Hospitals, Clinics & Others, Mail Orders, Other), by Distributor Type (Ethical/Branded Pharma Products Distributors, Generic Pharma Products Distributors, Propaganda Cum Distribution (PCD) Franchise, OTC/Institutional Supply Pharma Distributors, Other), by Product Type (Prescription Drugs Wholesaling & Distribution, Antibiotics Wholesaling & Distribution, OTC Products Wholesaling & Distribution, Antiseptics Wholesaling & Distribution, Supplement Products Wholesaling & Distribution, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.
The global pharma wholesale and distribution market was valued at US$xx million in 2020 and is projected to grow at a CAGR of xx% during the forecast period 2021-2031.
Connected Trends That Lay Great Importance On Individual Treatment Are The Consequence Of Personalized Care
Personalized care is the result of two connected trends that place a major emphasis on treating patients on an individual basis. Personalized wellness is an individualised approach to holistic wellbeing that assesses an individual's risk of developing a disease or having adverse treatment reactions based on biologic data. Personalized medicine is a type of medicine that uses genetics to evaluate a person's illness vulnerability, specify preventive measures, and target specific therapies to lower overall health risks.
How has COVID-19 had a significant negative impact on the Pharma Wholesale and Distribution Market?
The COVID-19 epidemic is clearly both a health and economic calamity for the entire world. There have been concerns about the pharmaceutical supply chain since the stoppage of industrial activity in China and India, even before the World Health Organization (WHO) declared the spread of the SARS-CoV-2 virus a pandemic.
While some manufacturing resumed in China in April, the virus spread in many other parts of the world. According to a study done by the industry newspaper Pharmaceutical Technology in mid-April 2020, 24 percent of 3,617 respondents were extremely convinced that medications will not be disrupted, while a comparable amount (22 percent) were extremely skeptical. 1 Another 23% were somewhat confident, while 20% were somewhat skeptical. Clearly, there was no consensus on the long-term impact of the pandemic.
Several months later, the uncertainty persists. Many areas of the United States experienced significant increases in cases after reopening their economies, with several reinstating modified stay-at-home and company closure/reduced operation orders. Other countries have had success in limiting pockets of case surges by implementing robust track-and-trace systems and mandating mask wear. The virus will undoubtedly continue to wreak devastation until a vaccine is discovered, extensively distributed, and delivered to the vast majority of the world's population.
How this Report Will Benefit you?
Visiongain’s 450+ page report provides 300 tables and 284 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global pharma wholesale and distribution market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Pharma Wholesale and Distribution. Get the financial analysis of the overall market and different segments including type, distributor type, product type and capture higher market share. We believe that high opportunity remains in this fast-growing pharma wholesale and distribution market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.
What are the current market drivers?
Many Health-Care Organizations Are Seeing Organic Growth At Levels That Their Supply Networks Were Never Designed To Handle
Due to an ageing population and high rise in subsidized spending through programs like Medicare and Medicaid, the healthcare industry in world has developed dramatically in recent years. For the first time, healthcare jobs have outpaced both manufacturing and retail jobs, and healthcare mergers and acquisitions have reached new highs. Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort. And, at the core of this issue, inefficiencies in the supply chain threatens not only to increase profitability, but also to reduce patient care. Whether the firm extends its geographic presence by purchasing, adding services through a pharmaceutical merger or simply reviewing your traditional processes, optimizing your supply chain has never been more important. And it is often the first move to consolidate or streamline your IT infrastructure.
Multinational corporations outsource all of their operations to a single national distributor
Foreign pharmaceutical businesses without local subsidiaries in Asia Pacific choose to outsource distribution and manage product registration in-house. Multinational corporations outsource all of their operations to a single national distributor. The region's distribution and wholesale requirements are quite diverse. Markets with a high level of maturity, such as Japan and Australia, necessitate a highly efficient distribution setup. Despite the fact that the country is dealing with enormous distances, next-day direct-to-pharmacy distribution is standard across Australia. For the next few years, the developed markets will focus on innovation and patient-specific logistics solutions for novel medications.
Where are the market opportunities?
Complexity Decreasing: From Raw Data To Operating Analytics
In any healthcare facility or department the amount of information generated might be astonishing. Without a strategy plan, firms can lack precious insights to assist them detect trends and exploit opportunities without collection of, integrating and properly evaluating such data. The appropriate analysis may prevent stockpiles or excess stocks of products, identify crucial details to ensure conformity and improve refunds, and synchronise the whole supply chain with quality assurance and operational efficiency. As hospitals allocate nearly a third of their operating costs for the management of the supply chain, analytics should be given priority. To define agreed goals, a multidisciplinary team of doctors, IT specialists, and support workers should be consulted before developing an analytics approach. Organizations can empower the combined team to look beyond their own data sets, concentrating instead on how data from their immediate sphere of influence fits into the bigger picture. This is critical since supply chains are made up of layers upon layers of interdependent components, such as medical supplies, drugs, suppliers, pricing tiers, and so on.
Organizations Can Swiftly Identify And Overcome Gaps, Disconnects, And Other Challenges That Can Obstruct Profitability
Optimization of the supply chain is obviously a task that health care decision makers merit and require attention. However, the time, planning and practical project management involved in these initiatives tend in many situations to be understated by the executives and the personnel. While it can be tenting for companies to assign extra jobs for those eager to save money, it is crucial that the time and costs of utilising skilled physicians are taken into account in order to carry out novel tasks that cannot, by nature, be their focus. Organizations can swiftly identify and overcome gaps, disconnects, and other challenges that can obstruct profitability by engaging with an experienced supply chain consultant from the outset. Moreover, streamlining and standardising the combined supply chain allows them to operate as a single entity, ensuring that patients remain at the centre of the newly defined continuum of care.
The major players operating in the pharma wholesale and distribution market are Morris and Dickson, Alfresa Holdings, Walgreens Boots Alliance, Inc, AmerisourceBergen Corporation, Sinopharm Group Co. Ltd, Suzuken Co Ltd, Shanghai Fosun Pharmaceutical (Group) Co., Ltd, China Resources Pharmaceutical Group Limited, Smith Drug Company, CuraScript SD, Cardinal Health, Inc., Mutual Drug Company, CR Pharmaceutical, McKesson Corporation, Medipal Holdings Corporation, PHOENIX Group, Mawdsley-Brooks, Prodigy Health, Fortissa, These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The antibiotics market was valued at US$44,567.3 million in 2022 and is projected to grow at a CAGR of 4.15% during the forecast period 2023-2033.
31 January 2023
The global Clinical Trial Supplies market was valued at US$ 2,617.7 million in 2022 and is projected to grow at a CAGR of 9.32% during the forecast period 2023-2033.
31 January 2023
The global Meningococcal Vaccines market was valued at US$3,268.6 million in 2022 and is projected to grow at a CAGR of 6.32% during the forecast period 2023-2033.
31 January 2023
The global Human Microbiome market was valued at US$186.8 million in 2022 and is projected to grow at a CAGR of 25% during the forecast period 2023-2033.